KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

ClearPoint Neuro (CLPT) Research & Development (2018 - 2026)

ClearPoint Neuro's Research & Development history spans 13 years, with the latest figure at $3.2 million for Q4 2025.

  • On a quarterly basis, Research & Development fell 2.85% to $3.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.9 million, a 12.14% increase, with the full-year FY2025 number at $13.9 million, up 12.14% from a year prior.
  • Research & Development hit $3.2 million in Q4 2025 for ClearPoint Neuro, down from $3.5 million in the prior quarter.
  • Over the last five years, Research & Development for CLPT hit a ceiling of $3.8 million in Q2 2025 and a floor of $1.6 million in Q1 2021.
  • Historically, Research & Development has averaged $2.9 million across 5 years, with a median of $3.0 million in 2022.
  • Biggest five-year swings in Research & Development: surged 159.73% in 2021 and later dropped 13.45% in 2024.
  • Tracing CLPT's Research & Development over 5 years: stood at $3.1 million in 2021, then fell by 4.75% to $2.9 million in 2022, then decreased by 9.4% to $2.7 million in 2023, then grew by 25.64% to $3.3 million in 2024, then dropped by 2.85% to $3.2 million in 2025.
  • Business Quant data shows Research & Development for CLPT at $3.2 million in Q4 2025, $3.5 million in Q3 2025, and $3.8 million in Q2 2025.